Rujukan

Dokumen kawal selia, literatur semakan rakan sebaya, pendaftaran ujian dan sumber rasmi

FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma

U.S. Food and Drug Administration. Notis kelulusan ubat FDA, 2026

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma

Daraxonrasib versus chemotherapy in previously treated metastatic pancreatic cancer (RASolute 302)

O'Reilly EM, Wolpin BM, et al.. New England Journal of Medicine, 2026

https://www.nejm.org/
Daraxonrasib in previously treated RAS-mutant non-small-cell lung cancer: phase 1/2 results

Hong DS, et al.. New England Journal of Medicine, 2026

https://www.nejm.org/

RASolute 302: Phase 3 study of daraxonrasib vs. standard of care chemotherapy in previously treated metastatic PDAC

ClinicalTrials.gov. NCT06625320, 2024

https://clinicaltrials.gov/study/NCT06625320
RASolve 301: Study of daraxonrasib in patients with RAS mutated NSCLC

ClinicalTrials.gov. NCT06881784, 2025

https://clinicaltrials.gov/study/NCT06881784
RMC-6236-001: First-in-human study of RMC-6236 in RAS-mutant solid tumors

ClinicalTrials.gov. NCT05379985, 2022

https://clinicaltrials.gov/study/NCT05379985

Laman web rasmi Revolution Medicines

Revolution Medicines, Inc.. Laman web korporat

https://www.revmed.com
Pencari ujian klinikal Revolution Medicines

Revolution Medicines, Inc.. Maklumat ujian klinikal

https://revmedclinicaltrials.com/

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial

Revolution Medicines. Siaran akhbar syarikat, 2026

https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib

Revolution Medicines. Siaran akhbar syarikat, 2025

https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-fda-breakthrough-therapy
Daraxonrasib Nearly Doubles Survival in Previously Treated Metastatic Pancreatic Cancer

The ASCO Post. Liputan kongres ASCO 2026, 2026

https://ascopost.com/issues/june-10-2026/daraxonrasib-nearly-doubles-survival-in-previously-treated-metastatic-pancreatic-cancer/